NEO (NeoGenomics) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics:

Total Revenue: $201.7 million, up 11% year-over-year, exceeding guidance of 9% growth.

Clinical Revenue: Grew 14% year-over-year, driven by a 2% increase in test volumes and a 12% increase in Average Unit Price (AUP).

NGS Revenue: Increased 26% year-over-year, now comprising one-third of clinical revenue.

Adjusted Gross Margin: Expanded by 260 basis points to 48.1%.

Adjusted EBITDA: Rose 36% year-over-year to $14.4 million.

Nonclinical Revenue: Declined 15% year-over-year, primarily due to a 26% drop in Pharma revenue, partially offset by 17% growth in Oncology Data Solutions.

Cash Position: Ended the quarter with $145.5 million in cash and cash equivalents.

2Strategic Updates and Business Highlights:

Market Position: NeoGenomics holds a 25% market share in hematology diagnostics and therapy selection.

Product Launches: Continued expansion of the PanTracer Family and RaDaR ST, targeting large markets in therapy selection and minimal residual disease (MRD).

Commercial Strategy: Reorganized sales teams into dedicated oncology and pathology ecosystems to enhance focus and accountability.

Lab of the Future Initiative: Ongoing investments in automation and digital pathology are expected to drive further margin improvements.

3Forward Guidance and Outlook:

Revenue Guidance: Raised to $802 million - $806 million for FY 2026, up from previous guidance of $797 million - $803 million.

Clinical Business Growth: Expected to grow in the low teens for the full year, with NGS growth anticipated in the mid-20s.

Nonclinical Business: Now expected to decline by high single digits for the year.

Adjusted EBITDA Guidance: Increased to $56 million - $58 million, representing over 30% growth year-over-year.

4Bad News, Challenges, or Points of Concern:

Nonclinical Business Weakness: The Pharma segment continues to face challenges, leading to a downward revision in expectations for the full year.

Volume Growth: Clinical volumes were slightly below expectations, impacted by the exit from a high-volume, low-value contract.

Competitive Pressures: The company is experiencing competitive takeaways, particularly in the MRD space, which could impact future growth.

5Notable Q&A Insights:

NGS Growth: Management expressed confidence in the durability of NGS growth, with expectations for continued strong performance in the back half of the year.

Pharma Business: While bookings increased significantly, the company acknowledged the need to improve pull-through rates to return to growth in this segment.

RaDaR ST Indications: Anticipated reimbursement for additional indications is expected to enhance market access and drive growth in 2027.

Operational Efficiency: Management is focused on reducing G&A expenses while balancing investments in sales and R&D to support growth. Overall, NeoGenomics reported a strong quarter with solid revenue growth and margin expansion, while also addressing challenges in its nonclinical segment and competitive pressures. The company remains optimistic about its strategic initiatives and future growth potential.